Founder of Meabco A/S in 2001 and Angel investor. Life long experience in commercial start ups.
Sergey holds a PhD in International Economy and has 17 years of experience in managing multinational research and development projects (nonclinical, clinical, cmc).
Fredrik holds a M.Sc. in International Business from Copenhagen Business School and have conducted studies in Advanced Corporate Finance at London Business School. Fredrik has 20 years of experience from senior positions within M&A, Strategy and Corporate Finance incl. 6 years as CFO at Lauritzen Fonden.
Henning ArboeAdministration & Project Manager
Henning has extensive practical experience in HR, and has worked as Manager for several international companies.
Andrey PanchenkoNonclinical Research
Andrey holds a degree of Medical Doctor from Pavlov Saint Petersburg State Medical University, PhD in pathophysiology and oncology.
More than 50 papers in medical journals in the field of pathology and oncology.
Beth CarinoBusiness Development
An international business executive with extensive experience in technical, operational management, project management, marketing, and business development. Specialized experienced in United States federal procurement contracting and preclinical contract research and development services
Meabco Advisory board
Prof. Thomas J. MacVittieRADIATION BIOLOGY, RADIATION BIOPHYSICS & CBRN Countermeasures Expert
Professor Emeritus at University of Maryland, School of Medicine, Radiation Oncology and Pathology, in Baltimore, MD.
Internationally-recognized radiobiology expert in the field of medical countermeasure development against the acute and delayed effects of acute radiation exposure with more than 200 peer-reviewed publications. M.S. and Ph.D in Radiation Biology from State University of New York (SUNY) in Buffalo, NY.
Prof. MacVittie served as advisor to the World Health Organization (WHO) Collaborating Centers in Radiation Emergency Medical Preparedness and Assistance, the NATO Radiation Research Study groups, the International Atomic Energy Agency (IAEA), the Canadian Defense Research Establishment, and the National Biodefense Science Board Federal Advisory Committee at the invitation of the Secretary of the U.S. Department of Health and Human Services (DHHS). He is a member of the Centers for Disease Control and Prevention (CDC) Strategic National Stockpile Radiation Working Group, the International Association of Radiopathology, the American Society of Hematology, the International Society of Experimental Hematology, the Radiation Research Society, and the International Society of Cellular Therapy. Prof. MacVittie is a member of the editorial board of Stem Cells and serves as ad hoc reviewer for the NIH/National Institute of Allergy of Infectious Diseases (NIAID) and the Department of Defense (DoD).
Prof. Viktor MeinekeDERMATOLOGY, VENEREOLOGY, ALLERGOLOGY & CBRN Countermeasures Expert
Prof. Dr. med. Viktor Meineke is a specialist in dermatology and venereology, and is an internationally-recognized expert in the field of radiation damage to the skin. He obtained his M.D. degree from the University of Mainz, completing his residency in Dermatology at the German Armed Forces Central Hospital in Koblenz with extension studies in dermatological radiation therapy at the Dermatology Clinics at Biederstein at Technische Universität Munchen (TUM) and at the Universität des Saarlandes Homburg. He also holds an MBA from the European Business School (EBS) Universität Oestrich-Winkel.
Prof. Dr. Meineke is the Founder and CEO of DermaManagement GmbH, a chain of 10 dermatology clinics in Germany. He is Professor at the TUM and at the University of Ulm. Previously, he was an Adjunct Professor at the Feinberg School of Medicine at Northwestern University in Chicago, IL. At the Bundeswehr Military Medical Academy, Prof. Dr. Meineke was Director of Chemical, Biological, Radiological, and Nuclear (CBRN) Division and Director of the university-affiliated Federal Research Institute.
Prof. Dr. Meineke is author of more than 150 original publications and is an ad hoc scientific advisor to the National Institutes of Health (NIH), the World Health Organization (WHO), the U.S. Food and Drug Administration (FDA), the International Atomic Energy Agency (IAEA), and the German Radiation Protection Board.
Alla ShapiroRADIATION MEDICAL COUNTERMEASURES, PEDIATRIC HEMATOLOGY ONCOLOGY & CBRN Countermeasures Expert
M.D. in Pediatrics from Bogomolets Kiev Medical School and Ph.D. in in pediatric hematology from the National Institute of Hematology and Blood Transfusion in Kiev, Ukraine. Pediatrics residency at Georgetown University Hospital, Georgetown University School of Medicine in Washington, DC and Pediatric Hematology-Oncology Clinical Fellowship at the National Cancer Institute (NCI) of the National Institutes of Health (NIH) in Bethesda, Maryland.
A world renowned medical expert on the effects and treatment of radiation exposure to humans, Dr. Shapiro’s career spans decades of experience highlighted by 20 years at the U.S. Food and Drug Administration (FDA), retiring as Medical Officer at the Counter-Terrorism and Emergency Coordination Staff (CTECS), an Office within the Center for Drug Evaluation and Research (CDER) providing scientific, regulatory, and policy guidance on the development and availability of safe, effective, and quality medical countermeasures (MCMs) for chemical, biological, radiological and nuclear threats and emerging infectious diseases. Also within the U.S. FDA’s CDER, Dr. Shapiro worked at the Division of Oncology Drug Products (DODP) in the evaluation of promising new cancer therapies.
Notably, Dr. Shapiro’s extensive experience leading to her career as one of the world’s leading experts in MCMs against radiation exposure was spurred on by her contributions as one of the first physician responders and researchers to the 1986 Chernobyl nuclear disaster.
Prof. Svend Aage EngelholmOncology and Radiation Oncology
Medical doctor from University of Copenhagen. Specialist in medical- and radiation oncology.
Professor Engelholm is DMSci and professor at University of Copenhagen, Denmark.
He worked experimentally at University of Copenhagen with cell kinetic studies in human small cell lung cancer and breast cancer, heterotransplanted into nude mice and in vitro. Professor Engelholm was among the first who demonstrated inherited heterogeneity and genetic instability in human tumors. Furthermore, he established a number of human small cell lung cancer cell lines.
Professor Engelholm established one of the biggest radiotherapy departments in Europe at Rigshospitalet in Copenhagen and established the first department with accelerator based cranial stereotactic treatment in Scandinavia.
The department was the first place in Scandinavia who treated patients with IMRT, introduced PET/CT based radiotherapy planning among the first sites in the world and together with Varian, was a part of the group who developed VMAT (RapidArc) for clinical use. As the first department in the world Rigshospitalet treated a patient with RapidArc.
Professor Engelholm established and was chairman for the DANLITE group who was the background of building a proton facility in Denmark.
Engelholm is educated in proton therapy at UPPEN Proton Center, Philadelphia.
Professor Engelholm was founder of the Danish Ovarian Cancer Study Group and chairman in 10 years.
Daily professor Engelholm are working at Rigshospitalet, University of Copenhagen and the Swedish Proton Center, Uppsala, Sweden with treatment of pediatric, brain- and gynecological cancer.
Professor Engelholm have published more than 250 peer reviewed papers and have been supervisor on 18 Ph.D. projects.
Prof. Stig LarsenClinical research Methodology and Statistics
Clinical research Methodology and Statistics
Norwegian University of Life Sciences (NULS), Norway
MSc in Mathematical Statistics with speciality in Medical Statistic, MD with speciality in Gastroenterology and DSC in Clinical Research Methodology
He is Professor in Controlled Clinical Research Methodology and Statistic at NULS and Research Director of the Nordic medical research Unit Meddoc
Former Head: Clinical research section, Centre of Epidemiology, NULS; Parexel/Medstat Nordic countries; Nordic Statistical Centre CIBA- GEIGY
He has 387 scientific papers in peer-reviewed international journals, primarily in clinical research methodology, gastroenterology and cancer. All together he has supervised 48 PhD-fellows in Medicine and Veterinary medicine and written three compendiums in clinical research methodology. Beside clinical cancer studies, Prof Larsen has focused on development of new stochastic-based clinical study design methodology such as Response Surface Pathway (RSP) designs. During the last years he has supervised four PhD-fellows in development of RSP and published 12 papers in this methodology.
Prof. Henrik HarlingSurgical Oncology
Associate Professor of Surgery, MD, Dr. Med, University of Copenhagen, Denmark.
Board certified specialist in General Surgery and Gastro-Intestinal Surgery. Former Head of Digestive Disease Center of Surgery, Gastroenterology and Hepatology at Bispebjerg University Hospital, Copenhagen. Surgical and Scientific Expert in Colorectal Cancer, Co-founder of Danish Colorectal Cancer Group, Chairman of Danish Colorectal Cancer Register, Member of National Health Boards and member of the Executive Committee of the Danish Cancer Society. Has published 115 scientific papers in peer-reviewed journals, primarily on GI cancer and treatment of late onset intestinal radiation damage. Since 2017 Prof. Harling has focused on drug development and clinical validation within prevention, mitigation and treatment of side effects to radiation besides developing a Functional Precision Medicine tool within colorectal, ovarian and pancreatic cancer by means of patient-derived 3D microtumor technology.
Meabco Board Members
Bent Østergaard has extensive management experience from a career of 50 years in international business. Bent Østergaard has held several top management positions such as CEO of Lauritzen Fonden and LF Investment ApS as well as CFO of J. Lauritzen A/S. He also has significant experience from board work among others from positions as Chairman of DFDS A/S, J. Lauritzen A/S and a number of other Danish and international companies.
Today Bent Østergaard focuses on board assignments and is chairman of Frederikshavn Maritime Erhvervspark A/S and Cantion A/S. In addition, Bent Østergaard is a board member of Desmi A/S, Jens og Margrethe With’s Fond, Durisol UK, Minervax ApS, Nanonord A/S and SmartVan A/S.
Bent Østergaard has been a member of the board of Meabco Holding A/S since 2011 and chairman since 2015.
Hans Carl, PhD, Secretary and former Chairman of Meabco, Chairman or board member of several companies and associations including chairman of an anti-cancer association. Regional coordinator of the French association on research of the side effects of radiation exposure. Former director in UNCTAD, the United Nations Conference on Trade and Development.
Tommy Thomsen is the CEO of Lauritzen Fonden (“LF”) and chairman of J. Lauritzen A/S. LF is the parent company of the shipping companies J. Lauritzen (wholly owned) and DFDS (42,5% holding), as well as the private limited company LF Investment ApS. LF Investment’s portfolio includes investments in companies in the offshore, ship owning, measuring equipment, biotechnology and real estate sectors.
Tommy Thomsen is also chairman of Den Danske Maritime Fond and C.W. Obel A/S. Tommy Thomsen is a board member of PSA International Pte Ltd, Chemical Transportation Group and Rederklubben. Tommy Thomsen is also on the advisory board of Canal de Panama and Portchain.
In addition to extensive management experience, Tommy Thomsen possesses in depth knowledge and global experience of business development, strategy and finance.
Philip Nyholm is a transactional / corporate lawyer and Managing Partner at DANDERS & MORE law firm. Philip Nyholm focuses on stock market law, company law, M&A as well as general commercial advice. Through a number of years, Philip has also been involved with several biotech companies and the challenges faced by this type of company.
Linda Sjöström is an experienced senior executive in the pharmaceutical industry and investment partner in the venture capital industry investing in and developing biotech companies with the aim of an IPO or sale to industrial partners. Linda has acted as chairmen and board member in numerous Boards of Directors in DK, Europe and the US. Linda is educated as Master of Science in Chemical Engineering.